Accelagen driving development of new candidate for COVID-19 Vaccine

September 1, 2020

1st September 2020

Accelagen is excited to announce the initiation of a new COVID-19 vaccine trial, commencing in Melbourne on Tuesday 1st September!

One of the largest vaccine manufacturer’s in the world has entrusted Accelagen to initiate this important first study to support the next stage of development of this novel vaccine. Following the successful demonstration of safety in the Phase 1 participant, we anticipate the progression to an expanded Phase 2 evaluation in October, with approximately 250 participants to be recruited.

Our Managing Director, Greg Plunkett has said, ‘Accelagen are delighted to contribute to the progression of COVID-19 vaccine candidates. Our team is working incredibly hard to ensure this trial has every resource needed to be a success. In partnership with Nucleus Network, we have benefited from the expedited ethics review and site start up activities. We extend our gratitude to our development partners in choosing Accelagen to be the trial sponsor.’

Since our establishment in 2010, Accelagen has worked in the development and execution of several vaccine trials across Australia. We have been working with international partners in developing therapeutics ranging from vaccines, prescription medicines, OTC products and medical devices. Our talented team has built a strong collaboration with key researchers and major clinical trial sites to ensure our clients achieve success for their product development pathways.

For more information on the study, please refer to the Australian New Zealand Clinical Trial Register (